Combination product for the treatment of neurological and/or psychiatric disorders

1. A pharmaceutical combination product consisting of active ingredients (i), (ii) and, optionally, a monoamine oxidase inhibitor:

(i) a compound described by the following formula (I), or salt thereof:

wherein,

R 1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

R 2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

R 3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

R 4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

R 5 is selected from the group consisting of deuterium ( 2 H) and protium ( 1 H); and

(ii) a 5-HT2A receptor antagonist.

2. The pharmaceutical combination product of claim 1 , wherein the compound described by formula (I) is selected from the group consisting of N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 4-phosphoryloxy-N,N-dimethyltryptamine, 4-hydroxy-N,N-dimethyltryptamine and O-acetylpsilocin, or salt thereof.

3. The pharmaceutical combination product of claim 1 , wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1-(1-Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AMOA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I-R91150.

4. The pharmaceutical combination product of claim 1 , wherein the combination product is prepared for oral, sublingual, buccal, intranasal, intravenous, intramuscular, subcutaneous, rectal, transdermal, topical and/or inhalation-mediated administration.

5. The pharmaceutical combination product of claim 1 , wherein the compound described by formula (I), or salt thereof, and the 5-HT2A receptor antagonist are physically separated.

6. The pharmaceutical combination product of claim 1 , wherein the 5-HT2A receptor antagonist alleviates or eliminates the hallucinogenic and/or psychedelic side effects caused by the compound described by formula (I).

7. The pharmaceutical combination product of claim 4 , wherein the combination product prepared for oral, sublingual, or buccal administration is contained within one or two tablets, wherein the one or two tablets comprise a therapeutically effective amount of a compound described by formula (I), or salt thereof, and the 5-HT2A receptor antagonist for the treatment of a psychiatric or neurological disorder in a human.

8. The pharmaceutical combination product of claim 7 , wherein the psychiatric disorder is selected from the group consisting of panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis, schizophrenia, substance addiction and personality disorders.

9. The pharmaceutical combination product of claim 7 , wherein the psychiatric disorder is depression, addiction, post-traumatic stress disorder, or a personality disorder.

10. The pharmaceutical combination product of claim 7 , wherein the neurological disorder is Parkinson's Disease.